$ACOG is a high growth opportunity The global market for Alzheimer’s treatment more than doubled from 2013 to a projected 2023 value of $13.3 billion. Realizing a high CAGR in this period of 10.5%, I’m expecting to see some strong continued growth in this industry.
Novel symptomatic therapies are becoming a much more routine form of care in the industry, which is where Alpha Cognition $ACOG/ $ACOG.V comes in.
$ACOG’s ALPHA-1062 therapy is a prodrug of an approved AChEI glutamine that has been designed to significantly reduce the side effects observed with other acetylcholinesterase inhibitors commonly used in the treatment of Alzheimer’s.
The improved side effect profile of 1062 can help optimize the effectiveness of treatment by enabling patients to start treatment at a therapeutic dose faster and stay on the therapy longer.
Reputable analysts seem to have already caught on to $ACOG as a high growth pre-revenue opportunity, which has me feeling highly optimistic about the company’s outlook.
$ACOG is currently remaining stable at a price of $1 and is valued at an MCAP of $61.5 million.
https://www.alphacognition.com/